Compare BMRA & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRA | ACON |
|---|---|---|
| Founded | 1971 | 2008 |
| Country | United States | United States |
| Employees | N/A | 11 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.4M |
| IPO Year | 1995 | N/A |
| Metric | BMRA | ACON |
|---|---|---|
| Price | $1.60 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 4.2K | ★ 34.2K |
| Earning Date | 04-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,311,000.00 | N/A |
| Revenue This Year | N/A | $87.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $2.34 |
| 52 Week High | $4.60 | $12.03 |
| Indicator | BMRA | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 34.61 | 27.51 |
| Support Level | N/A | $2.38 |
| Resistance Level | $1.75 | $3.54 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 16.57 | 8.54 |
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.